FINNENCE ▪ THE WIRE FILE
THE WIRE · № 75648
News■ Unclear/unknown
REGENXBIO to Host Investor Event Highlighting Surabgene Lomparvovec (Sura-vec) in Wet AMD on October 20
KINDNews
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES3
STORY SIZESTANDALONE
FIRST SEEN
LAST UPDATE
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
An investor event ahead of pivotal gene-therapy data flags a binary catalyst for the biotech later this year.
Gene-therapy readout looms as binary catalyst
CATALYST TO WATCH
Topline pivotal data in Q4 2026
MAIN RISK
Negative trial outcome crushes shares
FULL DISPATCH
Event to include clinical program overview and perspectives from leading retina specialists ahead of topline pivotal data readout anticipated in 4Q 2026 ROCKVILLE, Md., Oct. 12, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will host an investor event at 1:00 p.m....
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
Keenova Presents a New TERLIVAZ® (terlipressin) Exploratory Analysis at American College of Gastroenterology Annual Meeting2026-10-12 11:30 UTC
Keenova Presents a New TERLIVAZ® (terlipressin) Exploratory Analysis at American College of Gastroenterology Annual Meeting2026-10-12 11:30 UTC
→CORRELATIONshares Healthcare
Retension Pharmaceuticals exceeds target with $45M IPO2026-10-12 11:53 UTC
Retension Pharmaceuticals exceeds target with $45M IPO2026-10-12 11:53 UTC
→CORRELATIONshares Healthcare
Six-Month Pilot Study Demonstrates Improved Guideline Adherence Following Implementation of Standardized Cirrhosis Clinical Pathway2026-10-12 12:00 UTC
Six-Month Pilot Study Demonstrates Improved Guideline Adherence Following Implementation of Standardized Cirrhosis Clinical Pathway2026-10-12 12:00 UTC
→CORRELATIONshares Healthcare
POMDOCTOR LIMITED Highlights the Shift from Reactive Treatment to Predictive Healthcare2026-10-12 12:00 UTC
POMDOCTOR LIMITED Highlights the Shift from Reactive Treatment to Predictive Healthcare2026-10-12 12:00 UTC
→CORRELATIONshares Healthcare
Accord BioPharma Launches FILKRI™ (filgrastim-laha); Now Offers Both Long- and Short-Acting G-CSF Options2026-10-12 12:05 UTC
Accord BioPharma Launches FILKRI™ (filgrastim-laha); Now Offers Both Long- and Short-Acting G-CSF Options2026-10-12 12:05 UTC
→CORRELATIONshares Healthcare
Wisner Baum Lawsuit Alleges Syngenta Failed to Warn of Atrazine's Cancer Risks2026-10-12 12:09 UTC
Wisner Baum Lawsuit Alleges Syngenta Failed to Warn of Atrazine's Cancer Risks2026-10-12 12:09 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.